Negotiators in the EU reached a provisional deal on new rules to enhance public health protection by decreasing reliance on non-EU countries and boosting competitiveness in the pharmaceutical sector. The focus is on critical medicines such as antibiotics and vaccines. The agreement includes measures to stimulate investment in EU manufacturing, promote collaborative procurement, and support EU production through funding and procurement policies. The aim is to strengthen Europe's pharmaceutical industry, address shortages, and improve medicine security. The agreement needs approval from both Parliament and Council before implementation.